Targeting the endocannabinoid system: future therapeutic strategies.

@article{AizpuruaOlaizola2016TargetingTE,
  title={Targeting the endocannabinoid system: future therapeutic strategies.},
  author={Oier Aizpurua‐Olaizola and Izaskun Elezgarai and Irantzu Rico-Barrio and Iratxe Zarandona and Nestor Etxebarria and A. Usobiaga},
  journal={Drug discovery today},
  year={2016},
  volume={22 1},
  pages={
          105-110
        }
}

Figures and Tables from this paper

A Guide to Targeting the Endocannabinoid System in Drug Design

The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes,

The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases

This comprehensive review aimed to describe the complex interaction between CS and most common age-related diseases such as neuro-degenerative, oncological, skeletal, and cardiovascular disorders, together with the potential of various cannabinoids to ameliorate the progression of these disorders.

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases

This manuscript in-depth review will investigate the potential of the ECS in the treatment of various diseases, and to put forth the suggestion that many of these secondary metabolites of Cannabis sativa L. sativa may also have potential as lead compounds in the development of cannabinoid-based pharmaceuticals for a variety of diseases.

The endocannabinoid system in zebrafish and its potential to study the effects of Cannabis in humans

The zebrafish model can be used for elucidate some of the interactions of chemical components found in Cannabis sativa as it respects the 3Rs concept and reduced time and costs.

Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery

This review identifies advances in targeted drug delivery technologies that may permit access to the full pharmacotherapeutic potential of the ECS and highlights nanotechnology and surface modification aspects as a possible future approach for specific targeting.

Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders

Various types of cannabinoid administration, as well as nanotechnologies used to improve the bioavailability of these compounds in CNS diseases are discussed.

Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties

Increased aqueous solubility may enable new oral pharmaceutical delivery options for cannabinoids, as well as targeted delivery and release of cannabinoids within the intestines through glycoside prodrug metabolism.

Review: The Role of Cannabinoids on Esophageal Function—What We Know Thus Far

The current understanding of the ECS role in various esophageal functions and disorders is presented and new therapeutic modalities that may help advance current treatment options are presented.

Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

The role played by the endocannabinoid system in the physiopathology of Alzheimer, Parkinson, and Multiple Sclerosis is described, mainly at the neuroimmunological level and the evidence for the correlation between phytocannabinoids and their therapeutic effects is discussed.

Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update

A review of recent information regarding the roles of the ECS and the CB1 receptor signaling in the physiology and pathophysiology of energy and metabolic homeostasis introduces some recently identified signaling pathways in the mechanism of the pathogenesis of metabolic syndrome.
...

References

SHOWING 1-10 OF 62 REFERENCES

Review article: the endocannabinoid system in liver disease, a potential therapeutic target

Endocannabinoids are a family of potent lipid‐soluble molecules, acting on the cannabinoid receptors that mediate the effects of marijuana, which are located in the brain and peripheral tissues, including the liver.

Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease

This review describes the endocannabinoid (eCB) system’s role in modulating cell signaling within the brain and its regulation of monoamine neurotransmission and the stress axis and how dysfunction of this interaction can contribute to the development of psychiatric disorders.

Early phytocannabinoid chemistry to endocannabinoids and beyond

There have since been considerable advances in understanding of the endocannabinoid system and its function in the brain, which reveal potential therapeutic targets for a wide range of brain disorders.

The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.

  • C. Fowler
  • Biology, Medicine
    Handbook of experimental pharmacology
  • 2015
In vivo data for compounds inhibiting endocannabinoid metabolism have been reviewed, focussing on inflammation and pain and it is concluded that there is a continued potential for compounds inhibition in terms of drug development, but that it is wise not to be unrealistic interms of expectations of success.

The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications

The use of synthetic cannabinoids as new neuroprotective drugs to prevent and treat retinal diseases and the relevance of functional retinal measures in cannabis users to evaluate the impact of cannabis use on human retinal processing are supported.

Endocannabinoid metabolism by cytochrome P450 monooxygenases.

The endocannabinoid system--back to the scene of cardiometabolic risk factors control?

The development of new selective peripheral blockers that interrupt endocannabinoid action selectively in peripheral tissues and that have been suggested as an alternative approach to treat the metabolic consequences of obesity and related diseases, without undesirable central nervous system effects are described.

Endocannabinoids and Mental Disorders.

Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases and both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment.

Endocannabinoid signalling and the deteriorating brain

This work proposes a conceptual framework linking eCB signalling to the control of the cellular and molecular hallmarks of these processes, and categorizes the key components of endocannabinoid signalling that may serve as targets for novel therapeutics.
...